ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SNG Synairgen Plc

5.095
-0.035 (-0.68%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.035 -0.68% 5.095 4.70 5.49 5.00 4.70 4.70 180,475 16:35:24
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.54 9.46M

Synairgen plc Director/PDMR Shareholding (2402C)

15/10/2020 1:51pm

UK Regulatory


Synairgen (LSE:SNG)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Synairgen Charts.

TIDMSNG

RNS Number : 2402C

Synairgen plc

15 October 2020

Synairgen plc

("Synairgen" or the "Company")

Director Dealing/PDMR Announcement

Further to the announcement earlier today regarding the Placing, the Company makes the below announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014) in respect of the exercise of options by Richard Marsden, CEO of the Company, and John Ward, Finance Director of the Company.

Enquiries:

Synairgen plc

+44 (0) 23 8051 2800

Richard Marsden (Chief Executive Officer)

John Ward (Finance Director)

finnCap - Nominated Adviser and Joint Bookrunner +44 (0) 20 7220 0500

Geoff Nash / James Thompson / Charlie Beeson (Corporate Finance)

Alice Lane / Sunila de Silva (ECM)

Numis - Joint Bookrunner +44 (0) 20 7260 1000

James Black / Freddie Barnfield / Duncan Monteith

   Consilium Strategic Communications - Financial Media and Investor      +44 (0) 20 3709 5700 

Relations Adviser

Mary-Jane Elliott / Sue Stuart / Olivia Manser

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma, COPD and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') 
     / person closely associated with them ('PCA') 
a)  Name                          R ichard Marsden 
2.  Reason for notification 
a)  Position / status             Chief Executive Officer 
b)  Initial notification          Initial Notification 
     / amendment 
3.  Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                          Synairgen plc 
b)  LEI                           213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial  O ptions over o rdinary shares of 1p each 
     instrument 
     Identification code           GB00B0381Z20 
b)  Nature of the transaction     Exercise of options over Ordinary Shares 
c)  Price(s) and volume(s)        386,842 Ordinary shares of 1p each 
d)  Aggregated information        n/a 
     Aggregated volume Price 
e)  Date of the transaction       15 October 2020 
f)  Place of the transaction      London Stock Exchange 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') 
     / person closely associated with them ('PCA') 
a)  Name                                     John Ward 
2.  Reason for notification 
a)  Position / status                        Finance Director 
b)  Initial notification / amendment         Initial Notification 
3.  Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                                     Synairgen plc 
b)  LEI                                      213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument  O ptions over o rdinary shares of 1p each 
     Identification code 
                                              GB00B0381Z20 
b)  Nature of the transaction                Exercise of options over Ordinary Shares 
c)  Price(s) and volume(s)                   147,330 Ordinary shares of 1p each 
d)  Aggregated information                   n/a 
     Aggregated volume Price 
e)  Date of the transaction                  15 October 2020 
f)  Place of the transaction                 London Stock Exchange 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAAESFLNEFFA

(END) Dow Jones Newswires

October 15, 2020 08:51 ET (12:51 GMT)

1 Year Synairgen Chart

1 Year Synairgen Chart

1 Month Synairgen Chart

1 Month Synairgen Chart

Your Recent History

Delayed Upgrade Clock